Document is current

Article History

Received: 30 March 2026

Accepted: 10 July 2026

First Online: 25 July 2026

Declarations

Ethics approval and consent to participate: For in vivo experiments performed at BioInvent, all experimental animal studies were conducted under the approval of the Swedish Ethical Committee (approval numbers 5.8.18–17196/2018 and 5.8.18–19686/2022) and carried out in accordance with the Federation of Laboratory Animal Science Associations (FELASA) guidelines. For in vivo experiments performed at University of Southampton, all mice were housed in IVC units and maintained in accordance with the Animal (Scientific Procedures) Act 1986 and experiments were performed under approved project licenses (P4D9C89EA and PP5396109), and ethical review by local University of Southampton animal welfare committee (approval numbers 69840, 65400).

Consent for publication: Not applicable.

Competing interests: BioInvent International may financially benefit from this publication. RO, LM, MS, NY, PH, LVG, MCT, MY, JFB, AR, IK, IT, and BF are employed or partly research funded by BioInvent International. SAB reports grants and personal fees from BioInvent International during the conduct of the study; personal fees from LTZ Therapeutics, Epsilogen, ImCheck Therapeutics, and F-Star Therapeutics, and grants from Boehringer Ingelheim outside the submitted work. MSC reports grants from BioInvent International and personal fees from BioInvent International during the conduct of the study; personal fees from various Biotechs and Pharma outside the submitted work. The remaining authors declare no conflicts of interest.